113 related articles for article (PubMed ID: 22099778)
21. Improvement of islet engrafts by enhanced angiogenesis and microparticle-mediated oxygenation.
Montazeri L; Hojjati-Emami S; Bonakdar S; Tahamtani Y; Hajizadeh-Saffar E; Noori-Keshtkar M; Najar-Asl M; Ashtiani MK; Baharvand H
Biomaterials; 2016 May; 89():157-65. PubMed ID: 26970510
[TBL] [Abstract][Full Text] [Related]
22. Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R⁻/⁻) mice.
Poti F; Costa S; Bergonzini V; Galletti M; Pignatti E; Weber C; Simoni M; Nofer JR
Vascul Pharmacol; 2012 Aug; 57(1):56-64. PubMed ID: 22459073
[TBL] [Abstract][Full Text] [Related]
23. FTY720 improves functional recovery after spinal cord injury by primarily nonimmunomodulatory mechanisms.
Norimatsu Y; Ohmori T; Kimura A; Madoiwa S; Mimuro J; Seichi A; Yatomi Y; Hoshino Y; Sakata Y
Am J Pathol; 2012 Apr; 180(4):1625-35. PubMed ID: 22417787
[TBL] [Abstract][Full Text] [Related]
24. The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY720.
Petrie Aronin CE; Shin SJ; Naden KB; Rios PD; Sefcik LS; Zawodny SR; Bagayoko ND; Cui Q; Khan Y; Botchwey EA
Biomaterials; 2010 Sep; 31(25):6417-24. PubMed ID: 20621764
[TBL] [Abstract][Full Text] [Related]
25. Effects of VEGF loading on scaffold-confined vascularization.
Lindhorst D; Tavassol F; von See C; Schumann P; Laschke MW; Harder Y; Bormann KH; Essig H; Kokemüller H; Kampmann A; Voss A; Mülhaupt R; Menger MD; Gellrich NC; Rücker M
J Biomed Mater Res A; 2010 Dec; 95(3):783-92. PubMed ID: 20725981
[TBL] [Abstract][Full Text] [Related]
26. Engineering in vivo gradients of sphingosine-1-phosphate receptor ligands for localized microvascular remodeling and inflammatory cell positioning.
Ogle ME; Sefcik LS; Awojoodu AO; Chiappa NF; Lynch K; Peirce-Cottler S; Botchwey EA
Acta Biomater; 2014 Nov; 10(11):4704-4714. PubMed ID: 25128750
[TBL] [Abstract][Full Text] [Related]
27. Effect of FTY720 on some physiological indexes of Non-Obese Diabetic (NOD) Mice.
Chen X; Ye S; Zhang S; Li J; Zhu H; Zheng G; Lu Y; Wan H
Int J Mol Sci; 2012; 13(5):6129-37. PubMed ID: 22754354
[TBL] [Abstract][Full Text] [Related]
28. Co-electrospun poly(lactide-co-glycolide), gelatin, and elastin blends for tissue engineering scaffolds.
Li M; Mondrinos MJ; Chen X; Gandhi MR; Ko FK; Lelkes PI
J Biomed Mater Res A; 2006 Dec; 79(4):963-73. PubMed ID: 16948146
[TBL] [Abstract][Full Text] [Related]
29. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin.
Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M
Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350
[TBL] [Abstract][Full Text] [Related]
30. Depletion of T lymphocytes ameliorates cardiac fibrosis in streptozotocin-induced diabetic cardiomyopathy.
Abdullah CS; Li Z; Wang X; Jin ZQ
Int Immunopharmacol; 2016 Oct; 39():251-264. PubMed ID: 27494688
[TBL] [Abstract][Full Text] [Related]
31. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Schaper K; Dickhaut J; Japtok L; Kietzmann M; Mischke R; Kleuser B; Bäumer W
J Dermatol Sci; 2013 Jul; 71(1):29-36. PubMed ID: 23643308
[TBL] [Abstract][Full Text] [Related]
32. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice.
Nofer JR; Bot M; Brodde M; Taylor PJ; Salm P; Brinkmann V; van Berkel T; Assmann G; Biessen EA
Circulation; 2007 Jan; 115(4):501-8. PubMed ID: 17242282
[TBL] [Abstract][Full Text] [Related]
33. Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice.
Liu L; Wang C; He X; Shang W; Bi Y; Wang D
Microsurgery; 2007; 27(4):300-4. PubMed ID: 17477424
[TBL] [Abstract][Full Text] [Related]
34. Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs.
Penaranda C; Tang Q; Ruddle NH; Bluestone JA
Diabetes; 2010 Jun; 59(6):1461-8. PubMed ID: 20299465
[TBL] [Abstract][Full Text] [Related]
35. Three-dimensional, bioactive, biodegradable, polymer-bioactive glass composite scaffolds with improved mechanical properties support collagen synthesis and mineralization of human osteoblast-like cells in vitro.
Lu HH; El-Amin SF; Scott KD; Laurencin CT
J Biomed Mater Res A; 2003 Mar; 64(3):465-74. PubMed ID: 12579560
[TBL] [Abstract][Full Text] [Related]
36. Fabrication of uniaxially aligned 3D electrospun scaffolds for neural regeneration.
Subramanian A; Krishnan UM; Sethuraman S
Biomed Mater; 2011 Apr; 6(2):025004. PubMed ID: 21301055
[TBL] [Abstract][Full Text] [Related]
37. Distinctive degradation behaviors of electrospun polyglycolide, poly(DL-lactide-co-glycolide), and poly(L-lactide-co-epsilon-caprolactone) nanofibers cultured with/without porcine smooth muscle cells.
Dong Y; Yong T; Liao S; Chan CK; Stevens MM; Ramakrishna S
Tissue Eng Part A; 2010 Jan; 16(1):283-98. PubMed ID: 19839726
[TBL] [Abstract][Full Text] [Related]
38. Biocompatibility and degradation characteristics of PLGA-based electrospun nanofibrous scaffolds with nanoapatite incorporation.
Ji W; Yang F; Seyednejad H; Chen Z; Hennink WE; Anderson JM; van den Beucken JJ; Jansen JA
Biomaterials; 2012 Oct; 33(28):6604-14. PubMed ID: 22770568
[TBL] [Abstract][Full Text] [Related]
39. Structure and morphology changes during in vitro degradation of electrospun poly(glycolide-co-lactide) nanofiber membrane.
Zong X; Ran S; Kim KS; Fang D; Hsiao BS; Chu B
Biomacromolecules; 2003; 4(2):416-23. PubMed ID: 12625740
[TBL] [Abstract][Full Text] [Related]
40. Fabrication and structure analysis of poly(lactide-co-glycolic acid)/silk fibroin hybrid scaffold for wound dressing applications.
Shahverdi S; Hajimiri M; Esfandiari MA; Larijani B; Atyabi F; Rajabiani A; Dehpour AR; Gharehaghaji AA; Dinarvand R
Int J Pharm; 2014 Oct; 473(1-2):345-55. PubMed ID: 25051110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
